


World-Class CDMO Services

# Experience To Solve Your Microbiome Challenges





# Unlocking Your Microbiome Potential

Arranta Bio is delivering on its vision to build the best-in-class microbiome contract development and manufacturing organization (CDMO).

Our merger with veteran CDMO, Captozyme, and investment in expansion of the Gainesville, Florida facility, provides the dedicated manufacturing focus and expertise to deliver active pharmaceutical ingredients (APIs) for first-in-human Phase I clinical studies.

Arranta is committed to investing \$100,000,000 in building its capabilities to help microbiome pioneers. Our Florida facility, combined with construction of a commercial-ready manufacturing facility in Watertown, Massachusetts, establishes 100,000 square feet of facilities purpose built for aerobic, anaerobic and spore-forming organisms, and an experienced team ready to solve your challenges and take your project all the way from concept to commercialization.

Over a 10-year period, our Gainesville team produced **more than 125 species spanning 80 genera**, amassing an unrivaled understanding of the manufacturing needs for natural isolates and engineered live biotherapeutic products (LBPs).

Arranta is the market-leading CDMO dedicated to supporting pioneering innovators in the development of healthcare therapies based on LBPs targeting gut health and microbiome-related diseases.



10+

years of expertise



>125

species produced



100,000

sq.ft. of facilities

# Microbiome CDMO Services

## Types of Microorganisms



Aerobic



Anaerobic



Spore-forming

### Media Screening

- Proprietary media formulations
- Screening of up to 22 different animal-component-free media formulations for optimal growth of your microorganism

### Process Development & Scale-Up

- Cell banking optimization
- Research Cell Banks
- 3 L, 5 L, 14 L fermenters
- Optimization of fermentation parameters
- Optimization of cell harvest and downstream processing
- Proprietary panel of 16 pre-formulation cryoprotectants
- Lyophilization and formulation development

### Analytical Development, Qualification and Validation

- |                                  |   |
|----------------------------------|---|
| • Assay development              | • Sequencing (16S)                        |
| • Appearance                     | • Colony morphology                       |
| • pH & OD                        | • Endospore staining (spore forming test) |
| • Moisture content (Karl Fisher) | • Bioburden                               |
| • Potency                        | • Antibiotic sensitivity screen           |
| • Total cell count               | • Capsule weight                          |
| • Viable cell count              | • Disintegration                          |
| • Non-viable cell count          | • Uniformity of dose                      |
| • Live / dead staining           | • CCI                                     |
| • Gram staining                  |   |

### cGMP Drug Substance Manufacturing

- cGMP Master and Working Cell Banks
- 500 L cGMP fermenter
- Addition of 2x 2,000 L GMP fermenters (Q4, 2020)
- Cross contamination measures
- QC testing and QA release

### cGMP Drug Product Manufacturing

- Formulation
- Aseptic fill-finish
- QC testing and QA release
- Lyophilization
- Encapsulation (Q3, 2020)
- Primary packaging

### Quality Assurance & Regulatory Support

- Compliant with cGMP (US FDA)
- Support package available for IND documentation

### Stability Studies

- Stability studies conducted according to ICH Q1 and ICH Q5 guidelines
- -70°C, -20°C, +5°C, +25°C/60% RH, +30°C/65% RH and +40°C/75% RH conditions available for stability studies

### Long-Term Storage (cGMP)


- Temperature-mapped cGMP storage of MCB and WCB
- Temperature-mapped cGMP storage of Drug Substance or Drug Product
- Annual Report

# Facilities Purpose Built For Microbiome


Arranta Bio is exclusively dedicated to providing process development and cGMP manufacturing services for natural isolates and engineered live biotherapeutic products (LBPs) targeting diseases linked to the human microbiome.

Our Center of Excellence for Process Development & Early Clinical Supply is an expansion of the former Captozyme facility in Gainesville, Florida, where our expert team continues a legacy of 10 years dedicated to developing and scaling up processes for aerobic, anaerobic and spore-forming organisms.

We are also working on bringing online our commercial-ready cGMP facility in Watertown, Massachusetts by late 2020, which will offer large-scale manufacturing using state-of-the-art equipment, enabling Arranta Bio to take your microbiome projects from concept to commercial supply.



## Microbiome by the Numbers



**Human Microbiome**  
~3,300,000 genes



**Human Genome**  
~22,000 genes

**37 trillion**

estimated average number of cells in a human

**10-100 trillion**

number of symbiotic microbial cells in one person

**1,200**

species of microbes found in human intestines

**>100**

species of microbes living in a human stomach

**ARRANTABIO**

**Headquarters & Commercial-Ready cGMP Manufacturing**  
650 Pleasant Street  
Watertown, MA 02472

**Process Development & GMP Manufacturing**  
1622 NW 55th Place  
Gainesville, FL 32653

T. +1 352 363 2912  
E. [info@arrantabio.com](mailto:info@arrantabio.com)

[www.arrantabio.com](http://www.arrantabio.com)